Price to book forward of Collegium Pharmaceutical, Inc. – NASDAQ:COLL
This page from TradingView provides a financial data point for Collegium Pharmaceutical, Inc. (NASDAQ: COLL), specifically its "Price to book forward." The content is otherwise minimalistic, functioning as a data point within a larger financial platform.
Price to sales forward of Collegium Pharmaceutical, Inc. – FWB:354
This article provides the "Price to sales forward" value for Collegium Pharmaceutical, Inc. (FWB:354). It presents the current value and indicates that the market is closed with no trades. The content primarily focuses on financial data for this specific company.
Price to sales forward of Collegium Pharmaceutical, Inc. – NASDAQ:COLL
This article provides financial information for Collegium Pharmaceutical, Inc. (NASDAQ: COLL), specifically focusing on its forward price-to-sales ratio. It lists the company's ticker symbol, market, and offers an overview of its financials, news, and other related data on TradingView. The content itself seems to be more of a navigational page or a data placeholder from a financial platform rather than a detailed analysis.
Price to earnings forward of Collegium Pharmaceutical, Inc. – FWB:354
The article presents information on the "Price to earnings forward" metric for Collegium Pharmaceutical, Inc. (FWB:354) as displayed on TradingView. It indicates that the data is presented without specific values, focusing on the company's financial overview within the Frankfurt Stock Exchange listing. The content primarily lists navigation elements and disclaimers for data sources.
If You Invested $1,000 in Collegium Pharmaceutical Inc (COLL)
This article analyzes the historical returns of investing $1,000 in Collegium Pharmaceutical Inc (COLL) over various periods, showing its performance relative to the S&P 500. It details the company's business, focusing on its pain management portfolio and neuropsychiatry division (JORNAY PM for ADHD), and outlines its commercial strategy, financial reporting, and regulatory environment. The data highlights COLL's annual performance, including its compound annual growth rate and key yearly returns.
COLL - Collegium Pharmaceutical Inc Website Traffic and Mobile Apps Usage
This article provides comprehensive financial data, news, and insider transaction details for Collegium Pharmaceutical Inc (COLL). It includes stock performance metrics, analyst ratings, key financial figures, and a list of recent company announcements and insider trading activities.
Is Collegium Pharmaceutical (COLL) A Bargain On Its Azstarys Deal And 2026 Guidance?
Collegium Pharmaceutical (COLL) recently acquired the ADHD drug Azstarys for approximately US$655.6 million, expanding its central nervous system stimulant portfolio and updating its 2026 financial guidance. Despite strong share price returns, the stock trades at US$37.03, significantly below an analyst target of US$54.33, suggesting it is undervalued. The company's differentiated pain portfolio with abuse-deterrent technologies is expected to drive future growth, though concentration in its maturing pain portfolio and exposure to opioid regulation pose potential risks.
Is Collegium Pharmaceutical (COLL) A Bargain On Its Azstarys Deal And 2026 Guidance?
Collegium Pharmaceutical (COLL) acquired the ADHD drug Azstarys for $655.6 million, updating its 2026 financial guidance. The company’s stock, currently trading at $37.03, is considered undervalued with a fair value of $54.33, driven by steady revenue expansion and a strong earnings profile, particularly due to its differentiated pain portfolio. However, risks like concentration in a maturing pain portfolio and opioid regulation could challenge this optimistic valuation.
Collegium Pharmaceutical Stock Gains 12% in Three Months: Here's Why
Collegium Pharmaceutical (COLL) stock has risen 12% in the last three months due to investor confidence in its growing commercial portfolio and long-term strategy. Key drivers include the strong performance of its ADHD drug Jornay PM and the recent acquisition of Azstarys, which expanded its central nervous system portfolio and is expected to boost future earnings. The company also maintains a stable pain management business, further contributing to its positive outlook.
Collegium Pharmaceutical Stock Gains 12% in Three Months: Here's Why
Collegium Pharmaceutical (COLL) stock has risen 12% in the last three months, fueled by investor confidence in its growing commercial portfolio and strategic acquisitions. Key drivers include the strong performance of Jornay PM for ADHD and the recent acquisition of Azstarys, which enhances its ADHD market position and led to increased 2026 financial guidance. The company also maintains a stable pain management business, providing consistent revenue.
Collegium (NASDAQ: COLL) details $655.6M AZSTARYS acquisition terms
Collegium Pharmaceutical, Inc. (NASDAQ: COLL) filed an amended Form 8-K detailing the terms of its $655.6 million cash acquisition of AZSTARYS, an ADHD treatment, from GPC Commave Holding, LLC and Commave Sub, LLC. The purchase was funded by $355.6 million from existing cash and $300 million from a delayed draw term loan. The company may also pay an additional $135 million upon achieving certain commercial and manufacturing milestones for AZSTARYS.
COLL Forecast — Price Target — Prediction for 2027
This article provides a forecast for Collegium Pharmaceutical, Inc. (COLL) stock, including analyst price targets, past performance, and financial data. It highlights that analysts have a maximum price estimate of $60.00 and a minimum of $45.00 for COLL. The report also details current stock price, market capitalization, recent earnings, revenue, and future earnings expectations.
Collegium Pharmaceutical, Inc. Actuals & Estimates (NASDAQ:COLL)
This article provides an overview of Collegium Pharmaceutical, Inc. (NASDAQ: COLL) stock, including its current price, historical performance, and analyst forecasts. It details financial actuals and estimates for the company, covering income statements, balance sheets, and cash flow, along with key metrics like market capitalization and EBITDA. The report also addresses frequently asked questions about COLL's stock, such as earnings dates, revenue, net income, and dividend policy.
Collegium Pharmaceutical Inc (COLL) Institutional Confidence
Collegium Pharmaceutical Inc (COLL) has an institutional shareholding score of 10.00, placing it first in the Pharmaceuticals industry. The institutional shareholding proportion is 119.28%, a decrease of 6.89% quarter-over-quarter. James Simons is the largest institutional shareholder, holding 4.53% of shares outstanding.
Did Collegium Pharmaceutical’s Profitability Surge and Efficiency Gains Just Shift COLL’s Investment Narrative?
Collegium Pharmaceutical recently reported strong quarterly results with significant revenue growth and a large increase in net profit, suggesting that operational adjustments are improving earnings. This positive performance, coupled with reaffirmed full-year 2026 revenue guidance of US$805 million to US$825 million, strengthens the company's short-term investment narrative. However, long-term concerns persist regarding generic competition and pricing pressure on its core opioid-based products.
Did Collegium Pharmaceutical’s Profitability Surge and Efficiency Gains Just Shift COLL’s Investment Narrative?
Collegium Pharmaceutical (COLL) recently reported significant year-over-year revenue growth and a substantial increase in net profit, indicating that recent investments are improving profitability and operational efficiency. This positive financial performance potentially shifts the investment narrative, providing clearer guidance for investors despite lingering concerns about generic competition and pricing pressure on its opioid products. The company has reaffirmed its full-year 2026 revenue guidance, aligning it with improved profitability and efficiency scores.
Collegium Pharmaceutical Inc (COLL) Technical Analysis: Support, Resistance, Indicators & Moving Averages
Collegium Pharmaceutical Inc (COLL) has a current price momentum score of 8.99, ranking 40th in the Pharmaceuticals industry, with its stock trading between a resistance level of $36.00 and a support level of $30.61. Technical indicators show a mixed signal with 1 buy, 3 neutral, and 3 sell signals, while moving averages broadly suggest a "Sell" with 6 sell signals and no buy signals. Based on these technical analyses, the overall signal for COLL is "Sell" for today.
Collegium Pharmaceutical Inc (COLL) Earnings Forecast: Future EPS & Revenue Growth Estimates
Collegium Pharmaceutical Inc (COLL) has an earnings forecast score of 8.00, ranking 55th in the Pharmaceuticals industry. Analysts have an average target price of $48.00 for COLL, with a consensus of "Buy" based on 6 analysts. The company's expected revenue for the next quarter is $201.05M, and its EPS for the next quarter is projected to be $1.72.
Collegium Pharmaceutical Inc (COLL) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis for Collegium Pharmaceutical Inc (COLL), highlighting its current valuation score, market capitalization, and P/E ratio. The company's valuation score is 8.50, ranking 84 out of 157 in the Pharmaceuticals industry, with a P/E ratio of 14.22. The article notes that relevant data for P/B, P/S, and P/CF ratios have not been disclosed by the company.
Collegium Pharmaceutical Inc (COLL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a detailed breakdown of Collegium Pharmaceutical Inc's (COLL) revenue by business segment and region, using data updated on April 6. The main revenue drivers are Nucynta IR, Belbuca, and Xtampza ER, with all reported revenue originating from the United States. The company's market capitalization and P/E ratio are also noted.
Collegium Pharmaceutical Inc (COLL) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Collegium Pharmaceutical Inc (COLL), outlining major institutional holdings and different types of shareholders. It provides a breakdown of the largest shareholders, their proportional ownership, and recent changes in their holdings, along with historical institutional shareholding data and related ETF information.
Trading Systems Reacting to (COLL) Volatility
This article analyzes Collegium Pharmaceutical Inc. (NASDAQ: COLL) volatility using AI models, identifying a mid-channel oscillation pattern and an exceptional 86.1:1 risk-reward setup. It outlines specific position, momentum, and risk-hedging trading strategies, along with multi-timeframe signal analysis, including strong near-term and long-term positive sentiment. The analysis highlights key support and resistance levels to guide trading decisions.
[Form 4] COLLEGIUM PHARMACEUTICAL, INC Insider Trading Activity
COLLEGIUM PHARMACEUTICAL, INC director Gino Santini exercised stock options to acquire 8,700 shares of common stock at $16.49 per share. Following this transaction, Santini directly holds 112,483 shares of common stock, and the exercised option is fully utilized. The Form 4 filing indicates no sales, only the conversion of derivative securities into directly held shares.
Collegium Pharmaceutical (Nasdaq:COLL) - Stock Analysis
This report provides an in-depth stock analysis of Collegium Pharmaceutical (Nasdaq:COLL), highlighting its current market valuation, future growth prospects, past performance, and financial health. The company is currently trading 36.7% below its estimated fair value with earnings projected to grow by 41.91% annually. Recent insider selling and a high debt level are noted as risks, while the company's expansion into the ADHD market with acquisitions like AZSTARYS alongside its pain management portfolio is a key strategic move for future growth.
COLL: Steady 2026 Earnings Guidance Will Support Undervalued Affordable Medicines Theme
Collegium Pharmaceutical (COLL) has reaffirmed its full-year 2026 earnings guidance, projecting product revenues between US$805 million and US$825 million. Analysts have maintained their price target of US$54.33, indicating that the stock is considered 38.6% undervalued based on intrinsic discount, despite minor adjustments to valuation inputs. The company’s fair value estimate remains unchanged as of the latest update.
Collegium Pharmaceutical Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Collegium Pharmaceutical, Inc. announced that it granted 50,305 restricted stock units (RSUs) to 34 newly hired non-executive employees on June 1, 2026, under its 2026 Inducement Plan. These grants serve as a material inducement for their employment, in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over a three-year period, with one-third vesting on June 10, 2027, and the remainder in equal annual installments, subject to continued service.
Collegium Pharmaceutical Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Collegium Pharmaceutical, Inc. announced the granting of 50,305 restricted stock units (RSUs) to 34 newly hired non-executive individuals on June 1, 2026. These inducement grants were made under the company's 2026 Inducement Plan, adopted by the board of directors, in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over a three-year period, with one-third vesting in June 2027 and the remainder in equal annual installments thereafter, contingent on continued employment.
Collegium Pharmaceutical Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Collegium Pharmaceutical, Inc. announced it has awarded inducement grants comprising 50,305 restricted stock units (RSUs) to 34 newly hired non-executive employees under its 2026 Inducement Plan. These RSUs will vest over a three-year period, subject to continued employment, and were granted as a material inducement for employment in accordance with Nasdaq Listing Rule 5635(c)(4). The company specializes in biopharmaceutical medicines for central nervous system and pain conditions, with a focus on ADHD medications and responsible pain management.
COLL - Collegium Pharmaceutical Inc Stock Price and Quote
This article provides a detailed stock quote and company information for Collegium Pharmaceutical Inc. (COLL), including its last closing price, key financial metrics, trading performance, and recent analyst ratings. It also lists recent news headlines and insider trading activities.
COLL - Specialty Pharmaceuticals And Diversified Assets Will Drive Future Success
Collegium Pharmaceutical's fair value has been slightly increased to $54.33, reflecting updated assumptions regarding revenue growth, profit margins, and future P/E levels. The company reaffirmed its 2026 earnings guidance, projecting product revenues between $805 million and $825 million, and highlighted its focus on specialty pharmaceuticals and ADHD therapies. Despite potential risks from reliance on a maturing pain portfolio and rising fixed costs, analysts anticipate sustained revenue growth and margin expansion, forecasting annual revenue growth of 2.3% and profit margin increases to 28.5% over the next three years.
Collegium to Participate in 2026 Jefferies Global Healthcare Conference
Collegium Pharmaceutical, Inc. will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 3, 2026, at 1:20 p.m. ET. The company, focused on CNS and pain conditions, will webcast the event live, with a replay available for 90 days. This participation follows recent news of their acquisition of AZSTARYS® and strong first-quarter 2026 financial results.
Collegium to Participate in 2026 Jefferies Global Healthcare Conference
Collegium Pharmaceutical, Inc. announced its management will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on Wednesday, June 3, 2026, at 1:20 p.m. ET. A live webcast and replay of the event will be available on the company's investor relations website. Collegium Pharmaceutical focuses on delivering innovative medicines for central nervous system and pain conditions, with a portfolio that includes ADHD medications JORNAY PM® and AZSTARYS®.
Collegium to Participate in 2026 Jefferies Global Healthcare Conference
Collegium Pharmaceutical, Inc. announced its management will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 3, 2026, at 1:20 p.m. ET. A live webcast and replay will be available on the company's investor relations website. Collegium specializes in developing medicines for central nervous system and pain conditions, with a portfolio that includes ADHD medications and pain management solutions.
Collegium to Participate in 2026 Jefferies Global Healthcare Conference
Collegium Pharmaceutical, Inc. announced its management will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on Wednesday, June 3, 2026, at 1:20 p.m. ET. A live webcast and replay of the event will be available on the Investors section of the company's website. Collegium Pharmaceutical focuses on delivering innovative medicines for complex central nervous system and pain conditions, with a portfolio including differentiated ADHD medications like JORNAY PM® and AZSTARYS®.
Collegium to Participate in 2026 Jefferies Global Healthcare Conference
Collegium Pharmaceutical, Inc. announced its management will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on Wednesday, June 3, 2026, at 1:20 p.m. ET. A live webcast and replay of the fireside chat will be available on the Investors section of the company's website. Collegium focuses on delivering medicines for complex central nervous system and pain conditions.
How Strong Q1 Earnings and Executive Departures At Collegium Pharmaceutical (COLL) Have Changed Its Investment Story
Collegium Pharmaceutical reported strong Q1 2026 net income and reaffirmed its full-year product revenue guidance, signaling continued commercial momentum. However, upcoming departures of its Chief Commercial Officer and Chief Medical Officer introduce potential execution risks. The article examines how these events impact Collegium's investment narrative, particularly concerning its pain and ADHD drug portfolio and upcoming patent expirations.
COLL: Consistent 2026 Earnings Guidance Will Support Affordable Medicines Theme Upside
Collegium Pharmaceutical's fair value has been slightly increased by analysts, moving from $54.17 to $54.33, driven by updated assumptions in revenue growth, profit margins, and future P/E levels. The company reaffirmed its 2026 earnings guidance for product revenues, net, in the range of $805 million to $825 million, emphasizing consistency in its outlook. Additionally, Collegium Pharmaceutical reported no share repurchases in late 2025 and early 2026 and announced a multi-year partnership with Boston Legacy FC.
Collegium (NASDAQ: COLL) director sells 20 shares, holds 83,952
Collegium Pharmaceutical director John Gordon Freund reported selling 20 common shares at $34.05 each on May 18, 2026, in an open-market transaction. Following this sale, he directly holds 83,952 common shares and also has indirect interests in additional shares through affiliated entities. The Form 4 filing details his direct and indirect holdings, emphasizing that his beneficial ownership for indirect shares is limited to his proportionate pecuniary interest.
Director Nancy Lurker awarded 8,741 RSUs at Collegium (COLL)
Collegium Pharmaceutical director Nancy Lurker was granted 8,741 restricted stock units (RSUs) as part of her compensation, with each RSU representing one share of common stock. These RSUs will vest on the earlier of May 14, 2027, or the company's 2027 annual shareholder meeting, contingent on her continued service. Following this award, Lurker's direct holdings in Collegium Pharmaceutical total 26,758 shares.
Director at Collegium (NASDAQ: COLL) receives 8,741 RSUs in equity award
Collegium director Rita J. Balice-Gordon was granted 8,741 Restricted Stock Units (RSUs), increasing her direct holdings to 61,370 shares. These RSUs vest on the earlier of May 14, 2027, or the company’s 2027 Annual Meeting of Shareholders, provided she continues her service as a director. The grant, detailed in a Form 4 filing, is a form of equity compensation.
Collegium Pharmaceutical (COLL) director Donovan Glancy files initial Form 3
Collegium Pharmaceutical (COLL) director Donovan Michael Glancy has filed an initial Form 3, indicating his start as a reporting person for the company. This filing discloses his initial ownership of Collegium Pharmaceutical securities but does not report any transactions or derivative positions. A Form 3 is a mandatory SEC filing for new insiders, establishing a baseline for their holdings.
Director at Collegium (NASDAQ: COLL) awarded 8,741 RSUs in equity grant
Collegium Pharmaceutical director Gino Santini was granted 8,741 restricted stock units (RSUs) on May 14, 2026, as an equity award with a $0.00 purchase price. These RSUs will vest on the earlier of May 14, 2027, or the company's 2027 Annual Meeting of Shareholders, provided he continues his service as a director. Following this grant, Santini directly holds 103,783 shares of Collegium common stock, illustrating a form of compensation tied to continued service and company performance.
Collegium (COLL) director sells shares, exercises options and receives RSU grant
Collegium Pharmaceutical director John Gordon Freund recently sold 4,127 shares of common stock, exercised options for 8,700 shares, and received a grant of 8,741 restricted stock units (RSUs). After these transactions, his direct holdings stand at 83,972 shares, with additional indirect holdings through family partnerships and investment firms. The RSUs are set to vest by May 14, 2027, or the company's 2027 annual meeting, contingent on his continued board service.
Director Carlos V. Paya granted 8,741 RSUs at COLLEGIUM (NASDAQ: COLL)
COLLEGIUM PHARMACEUTICAL, INC. director Carlos V. Paya was granted 8,741 restricted stock units (RSUs) as compensation, increasing his direct holdings to 28,323 shares. These RSUs will vest on the earlier of May 14, 2027, or the company's 2027 Annual Meeting of Shareholders, contingent on his continued board service. The grant price was $0.00, and the settlement will be in common stock shares upon vesting or under specific conditions like the end of his board service or a change in control.
Director at Collegium (COLL) awarded 17,482 restricted stock units
Collegium Pharmaceutical director Michael Glancy was granted 17,482 restricted stock units (RSUs) on May 14, 2026, at no cash cost. These RSUs will vest in two equal tranches on or around May 14, 2027, contingent on his continued service to the board. Following this grant, Glancy holds 17,482 shares.
Collegium pharmaceutical director sells $142k in shares
A director at Collegium Pharmaceutical, John Gordon Freund, recently sold shares worth $142,546 and exercised stock options on May 14 and 15, 2026. Despite the stock being down 27% year-to-date, it has risen 12% over the past year. The company also reported strong Q1 2026 financial results with EPS of $1.76 and revenue of $193.5 million, surpassing analyst expectations.
Collegium Pharmaceutical (COLL) director receives 8,741 RSU grant, now holds 71,000 shares
Collegium Pharmaceutical director Garen G. Bohlin was granted 8,741 Restricted Stock Units (RSUs), increasing his direct holdings to 71,000 shares. These RSUs, which represent one share of common stock each, will vest on the earlier of May 14, 2027, or the company's 2027 Annual Meeting of Shareholders, contingent on his continued board service. The grant was a compensation-related award with no cash purchase involved.
Have Collegium Pharmaceutical Insiders Been Selling Stock?
Collegium Pharmaceutical (NASDAQ:COLL) has seen recent insider selling, including a notable divestment of US$162k by Independent Director Nancy Lurker, representing 20% of her holding. Over the last year, the Executive VP & Chief Medical Officer, Thomas Smith, also sold US$672k worth of shares, though at a price higher than the current market value. Despite these sales, the article notes that insider ownership still stands at 1.1% of the company, valued at approximately US$12 million.
Collegium Pharmaceutical stock (US19459E1029): opioid-pain specialist in focus after Q1 2026 earning
Collegium Pharmaceutical, a U.S.-focused specialty pharmaceutical company, is in the spotlight following its Q1 2026 earnings report, reaffirming its commitment to chronic pain medicines. The company's business model centers on extended-release opioid formulations, navigating strict prescribing rules and payer relationships in the U.S. market. Its revenue drivers, competitive position, and the broader trends in opioid regulation are crucial factors for investors to consider.
[SCHEDULE 13G/A] COLLEGIUM PHARMACEUTICAL, INC Amended Passive Investment Disclosure
COLLEGIUM PHARMACEUTICAL, INC. has filed an amended Schedule 13G/A disclosing that Eventide Asset Management, LLC, along with Finny Kuruvilla, M.D., Ph.D. and Robin C. John, beneficially own 1,424,282 shares, representing 4.5% of the company's common stock. Eventide has sole voting and dispositive power over these shares, while Kuruvilla and John report shared voting and dispositive power. The filing notes this is a passive investment, with the filers disclaiming beneficial ownership under Rule 13d-4.
